IP Library › Granted Patent US 9,737,569
Granted Patent B2
US 9,737,569 · App. 14/644,476 · Granted Aug 22, 2017

Compositions and methods for treatment of cardiovascular disorders

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,737,569
App. No.
14/644,476
Granted
Aug 22, 2017
Kind
B2
Abstract

ECM based compositions including amniotic membrane and methods for employing same to treat cardiovascular disorders.

Claims (5)

1. A composition for treating damaged cardiovascular tissue, comprising:

an extracellular matrix (ECM) composition consisting of acellular ECM from basement membrane of amniotic membrane and a combination of exogenously added growth factors selected from the group consisting of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) or transforming growth factor beta (TGF-β), wherein a growth factor augmented ECM composition is formed, whereby, when said growth factor augmented ECM composition is delivered to infarcted cardiovascular tissue, said growth factor augmented ECM composition induces angiogenesis, bioremodeling of said infarcted cardiovascular tissue and regeneration of new cardiovascular tissue structures with site-specific structural and functional properties.

2. A method for treating a cardiovascular disorder, comprising the steps of:

providing the extracellular matrix (ECM) composition according to claim 1 ; and

administering said ECM composition to infarcted cardiovascular tissue associated with said cardiovascular disorder.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 12, 2025
From: CORMATRIX CARDIOVASCULAR, INC.
To: CORVIVO CARDIOVASCULAR, INC.
Reel/Frame 070481/0747 →